Every finding in the evidence table: 382 rows, filterable

Every row

Filter

Area All 382 Care, carers and services 140 Medicines 85 Genes (not modifiable) 35 All modifiable factors together 27 Diet and supplements 23 Exercise and activity 21 Sleep, mood and social life 19 Hearing and vision 8 Alcohol, tobacco and cannabis 6 Infection and vaccination 5 Heart and metabolic health 4 Injury, delirium and falls 4 Environment 3 Cognitive activity 2

Question Both Prevention 190 Treatment 192

Direction Any Benefit 144 Harm 105 No effect 38 Mixed 37 No direction reported 58

Design Any meta-analysis 57 randomised trial 44 phase 3 trial 15 systematic review 9 phase 2 trial 10 cohort study 136 phase 1 trial 2 cross-sectional study 31 case-control study 14 modelling study 20 regulatory decision 7 company announcement 1 coverage determination 1 None 35

Showing 7 of 382 rows. One row per study per exposure: a study that tested two different things appears twice, once for each.

Scroll the table sideways to see every column.

Research and outcomes, 7 rows. Every row links to its source.
Exposure	Question	Direction	Outcome measured	Design	People	Effect size, as the source reported it	Source
Carer psychosocial / skills intervention Care, carers and services	Treatment	No effect why No difference from waitlist control on the primary burden outcome or on mood, WHOQOL-Bref or productivity; only the CarerQoL-VAS quality-of-life score was higher in the intervention group. The trial recruited 93 of a 194 target.	Carer burden on the Zarit Burden Interview at 6 and 12 weeks (primary); mood, quality of life, productivity	randomised trial	93	No statistically significant differences were observed between the intervention and control groups on the ZBI, CES-D, WHOQOL-Bref and WPAI:CG ... A statistically significantly higher mean CarerQoL-VAS score was found for the intervention group (mean difference = 0.75, 95% CL: 0.25 to 1.24, P = .003) over 6- and 12-weeks, compared to the control	Age and ageing 2026 ✓ Peer-reviewed PMID 41719424
Carer psychosocial / skills intervention Care, carers and services	Treatment	No effect why Burden fell in both arms with no significant difference between the two platforms. There was no untreated control, so the within-arm improvement cannot be separated from time or attention.	Caregiver burden at 6 months	randomised trial	240	Burden: GamePlan4Care effect size 0.50 (p<0.001); Resources4Care effect size 0.23 (p=0.030). Social support GP4C ES 0.21 (p=0.035); distress GP4C ES 0.30 (p=0.010)	Alzheimer's & Dementia 2025 ✓ Peer-reviewed PMID 41085219
Dementia care management / navigation Care, carers and services	Treatment	No effect why No difference between health-system care, community-based care or usual care on either primary outcome. Caregiver self-efficacy did improve in both active arms.	NPI-Q behavioural symptoms and caregiver strain (co-primary)	randomised trial	2,176	NPI-Q difference health-system vs community 0.30 (97.5% CI -0.18 to 0.78); caregiver self-efficacy vs usual care +0.70 (health system) and +0.85 (community), both significant	JAMA 2025 ✓ Peer-reviewed PMID 39878968
Dementia screening / case finding Care, carers and services	Treatment	No effect why No benefit and no harm: screening did not change family-member quality of life, preparedness or self-efficacy, and did not raise depression or anxiety. Only 5.1% screened positive.	Family-member quality of life (SF-36) at 24 months	randomised trial	1,808	24-month SF-36 mental component difference 0.58 (95% CI -0.18 to 1.33), not significant	JAMA Internal Medicine 2026 ✓ Peer-reviewed PMID 42008257
Palliative / advance care planning Care, carers and services	Treatment	No effect why The primary outcome did not improve. Emergency department visits and hospitalisations were lower (RR 0.45, 95% CI 0.31-0.65), which is a secondary outcome.	NPI-Q neuropsychiatric symptom severity at 24 months (primary)	randomised trial	201	ED visits + hospitalisations: RR 0.45 (95% CI 0.31-0.65); NPI-Q severity difference -0.24 (95% CI -2.33 to 1.84, not significant)	JAMA 2025 ✓ Peer-reviewed PMID 39878993
Cannabinoid (THC/CBD) for agitation in severe dementia Medicines	Treatment	No effect why No difference from placebo on the primary agitation outcome or other main behavioural outcomes. As-needed psychotropic use was lower during the active period, and no serious drug-related adverse events occurred.	Agitation on the Cohen-Mansfield Agitation Inventory (primary); as-needed psychotropic use; safety	randomised trial	25	not established — pubmed abstract results: "no significant difference was observed between active treatment and placebo for the cmai and other main behavioural…	Age and ageing 2026 ✓ Peer-reviewed PMID 42613673
Music therapy Sleep, mood and social life	Treatment	No effect why Neither choir singing nor group music therapy beat standard care. Country was the strongest predictor of the differences between sites.	MADRS depressive symptoms at 6 months	randomised trial	1,021	MADRS β 0.4 (95% CI -1.3 to 2.1) for choir singing; β 0.8 (95% CI -1.0 to 2.6) for group music therapy; neither significant	The Lancet Healthy Longevity 2025 ✓ Peer-reviewed PMID 41380710

How this table was built, and where it is weak →

Every row of the evidence table

Every row